Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BNP 7787; Disodium 2,2'-dithio-bis ethane sulfonate; LP 300; Tavocept

Latest Information Update: 18 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNumerik Pharmaceuticals
  • Developer BioNumerik Pharmaceuticals; Lantern Pharma
  • Class Alkanesulfonates; Chemoprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Glutaredoxin modulators; Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lung cancer
  • Phase II Non-small cell lung cancer
  • No development reported Peripheral nervous system diseases

Most Recent Events

  • 02 May 2017 Phase-II clinical trials in Non-small cell lung cancer in USA (IV) (Lantern Pharma pipeline, May 2017)
  • 17 Jan 2017 Lantern Pharma enters into a strategic collaboration agreement with Cancer Genetics Incorporated
  • 22 Apr 2015 Phase III development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top